Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zöchbauer-Müller, S.
Right arrow Articles by Gazdar, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zöchbauer-Müller, S.
Right arrow Articles by Gazdar, A. F.
The Oncologist, Vol. 7, No. 5, 451–457, October 2002
© 2002 AlphaMed Press

Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications

Sabine Zöchbauer-Müllera, John D. Minnab, Adi F. Gazdarb

a Clinical Division of Oncology, Department of Medicine I, University Hospital, Vienna, Austria; b Hamon Center for Therapeutic Oncology Research, The University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas, USA

Correspondence: Sabine Zöchbauer-Müller, M.D., Clinical Division of Oncology, Department of Medicine I, University Hospital, Währinger Gürtel 18-20, 1090 Vienna, Austria. Telephone: 43-1-40400-4429; Fax: 43-1-40400-4451; e-mail: sabine.zoechbauer{at}akh-wien.ac.at

Genetic abnormalities of proto-oncogenes and tumor suppressor genes are well-known changes that are frequently involved in lung cancer pathogenesis. However, another mechanism for inactivation of tumor suppressor genes is coming more and more into focus. Epigenetic inactivation of certain tumor suppressor genes by aberrant promoter methylation is frequently observed in lung carcinomas and seems to play an important role in the pathogenesis of this tumor type. While genetic abnormalities are associated with changes in DNA sequence, epigenetic events may lead to changes in gene expression that occur without changes in DNA sequence. Recent findings demonstrate that aberrant methylation can also be detected in the smoking-damaged bronchial epithelium from cancer-free heavy smokers, suggesting that aberrant methylation might be an ideal candidate biomarker for lung cancer risk assessment and monitoring of chemoprevention trials. Moreover, in vitro studies demonstrate that methylation can be reversed by demethylating agents resulting in gene re-expression. This concept is currently under investigation in clinical trials. In summary, recent studies demonstrate that aberrant methylation may be the most common mechanism of inactivating cancer-related genes in lung cancer, occurs already in smoking-damaged bronchial epithelium from cancer-free individuals, can be reversed in vitro by demethylating agents, and may be a useful biomarker for lung cancer risk assessment.

Key Words. Methylation • Tumor suppressor gene • Lung cancer • Preneoplastic lesion • Risk assessment




This article has been cited by other articles:


Home page
 JDRHome page
S.P. Barros and S. Offenbacher
Epigenetics: Connecting Environment and Genotype to Phenotype and Disease
Journal of Dental Research, May 1, 2009; 88(5): 400 - 408.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Luxen, S. A. Belinsky, and U. G. Knaus
Silencing of DUOX NADPH Oxidases by Promoter Hypermethylation in Lung Cancer
Cancer Res., February 15, 2008; 68(4): 1037 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote
The molecular epidemiology of lung cancer
Carcinogenesis, March 1, 2007; 28(3): 507 - 518.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Gu, D. Berman, C. Lu, I. I. Wistuba, J. A. Roth, M. Frazier, M. R. Spitz, and X. Wu
Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., December 15, 2006; 12(24): 7329 - 7338.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Shao, J. Berenguer, A. C. Borczuk, C. A. Powell, T. K. Hei, and Y. Zhao
Epigenetic Inactivation of Betaig-h3 Gene in Human Cancer Cells.
Cancer Res., May 1, 2006; 66(9): 4566 - 4573.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Wei, C. Balch, H. H. Paik, Y.-S. Kim, R. L. Baldwin, S. Liyanarachchi, L. Li, Z. Wang, J. C. Wan, R. V. Davuluri, et al.
Prognostic DNA methylation biomarkers in ovarian cancer.
Clin. Cancer Res., May 1, 2006; 12(9): 2788 - 2794.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Kim, J. W. Kim, J. Han, Y. M. Shim, J. Park, and D.-H. Kim
Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer.
Cancer Res., April 15, 2006; 66(8): 4049 - 4054.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. Vineis and K. Husgafvel-Pursiainen
Air pollution and cancer: biomarker studies in human populations
Carcinogenesis, November 1, 2005; 26(11): 1846 - 1855.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. A. Martey, C. J. Baglole, T. A. Gasiewicz, P. J. Sime, and R. P. Phipps
The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts
Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L391 - L399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Safar, H. Spencer III, X. Su, M. Coffey, C. A. Cooney, L. D. Ratnasinghe, L. F. Hutchins, and C.-Y. Fan
Methylation Profiling of Archived Non-Small Cell Lung Cancer: A Promising Prognostic System
Clin. Cancer Res., June 15, 2005; 11(12): 4400 - 4405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Guo, Y. Akiyama, M. G. House, C. M. Hooker, E. Heath, E. Gabrielson, S. C. Yang, Y. Han, S. B. Baylin, J. G. Herman, et al.
Hypermethylation of the GATA Genes in Lung Cancer
Clin. Cancer Res., December 1, 2004; 10(23): 7917 - 7924.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Kim, Y. M. Kwon, J. S. Kim, H. Lee, J.-H. Park, Y. M. Shim, J. Han, J. Park, and D.-H. Kim
Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung Cancer
J. Clin. Oncol., June 15, 2004; 22(12): 2363 - 2370.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Suzuki, N. Sunaga, D. S. Shames, S. Toyooka, A. F. Gazdar, and J. D. Minna
RNA Interference-Mediated Knockdown of DNA Methyltransferase 1 Leads to Promoter Demethylation and Gene Re-Expression in Human Lung and Breast Cancer Cells
Cancer Res., May 1, 2004; 64(9): 3137 - 3143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Topaloglu, M. O. Hoque, Y. Tokumaru, J. Lee, E. Ratovitski, D. Sidransky, and C.-s. Moon
Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer
Clin. Cancer Res., April 1, 2004; 10(7): 2284 - 2288.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.
Advertisement